In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $48. The company’s shares opened today at $33.05.
According to TipRanks.com, Livnat is ranked 0 out of 5 stars with an average return of -10.4% and a 29.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.
Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $45, representing a 36.2% upside.
In a report issued on April 30, Wedbush also reiterated a Buy rating on the stock with a $80 price target.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $79.08 million and quarterly net profit of $4.6 million. In comparison, last year the company earned revenue of $69.28 million and had a GAAP net loss of $19.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
